Los Angeles Capital Management LLC Makes New $63,000 Investment in Aldeyra Therapeutics, Inc. $ALDX

Los Angeles Capital Management LLC purchased a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,320 shares of the biotechnology company’s stock, valued at approximately $63,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ALDX. Public Employees Retirement System of Ohio bought a new stake in shares of Aldeyra Therapeutics in the second quarter worth about $25,000. Inspirion Wealth Advisors LLC bought a new stake in shares of Aldeyra Therapeutics during the second quarter worth $38,000. Corton Capital Inc. bought a new stake in Aldeyra Therapeutics in the 2nd quarter valued at $57,000. Wealth Enhancement Advisory Services LLC increased its holdings in Aldeyra Therapeutics by 150.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 27,286 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 16,376 shares in the last quarter. Finally, CWM LLC raised its stake in shares of Aldeyra Therapeutics by 1,164.4% in the 1st quarter. CWM LLC now owns 19,244 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 17,722 shares during the period. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Down 0.8%

Shares of ALDX stock opened at $4.91 on Wednesday. Aldeyra Therapeutics, Inc. has a 12-month low of $1.14 and a 12-month high of $7.20. The company has a market capitalization of $295.40 million, a PE ratio of -5.78 and a beta of 0.79. The firm has a 50 day moving average price of $5.20 and a two-hundred day moving average price of $4.47.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04. As a group, research analysts expect that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ALDX shares. BTIG Research reaffirmed a “buy” rating and issued a $9.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, November 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.50.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.